The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum

Takayuki Morikawa, Katsuji Hattori, Mayumi Kajimura, Makoto Suematsu

Research output: Chapter in Book/Report/Conference proceedingConference contribution

7 Citations (Scopus)

Abstract

Although cilostazol, an inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3), is known to exert a potent antiplatelet function by raising intracellular cAMP concentration, its effect on cerebral microcirculation upon an ischemic insult is not clearly understood. To examine effects of cilostazol on the global ischemic injury in the brain, we first measured the plasma leakage using modified Miles assay after mice had been subjected to 60 min of a bilateral common carotid artery (BCCA) occlusion followed by reperfusion for 4 h. Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage. This result led us to examine if the treatment with cilostazol recruits more capillaries leading to an increase in surface area for exchange and oxygen transport to tissues. To do so, we simultaneously measured degrees of tissue hypoxia and vessel perfusion. Pimonidazol was injected intraperitoneally 1 h before sacrifice and capillary patency was assessed by fluorescein isothiocyanate-labeled Lycopersicon esculentum lectin bound to the endothelial surface. Treatment with cilostazol markedly increased the capillary patency which was accompanied by a reduction in the hypoxic area.Although the treatment with cilostazol caused an increase in the flux of plasma proteins across endothelial barrier that may imply an adverse role after a BCCA occlusion, this increase in protein leakage was attributable to the increased surface area for exchange which in turn brought about a reduction in tissue hypoxia. Taken together cilostazol appears to produce a protective effect against the ischemic-reperfusion injury.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
Pages89-94
Number of pages6
Volume662
DOIs
Publication statusPublished - 2010

Publication series

NameAdvances in Experimental Medicine and Biology
Volume662
ISSN (Print)00652598

Fingerprint

Oxygenation
Cerebrum
Reperfusion Injury
Tissue
Common Carotid Artery
Microcirculation
Plasmas
Cyclic Nucleotides
Phosphoric Diester Hydrolases
cilostazol
Fluorescein
Brain Injuries
Reperfusion
Blood Proteins
Assays
Brain
Ion exchange
Perfusion
Oxygen
Fluxes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Morikawa, T., Hattori, K., Kajimura, M., & Suematsu, M. (2010). The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. In Advances in Experimental Medicine and Biology (Vol. 662, pp. 89-94). (Advances in Experimental Medicine and Biology; Vol. 662). https://doi.org/10.1007/978-1-4419-1241-1_12

The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. / Morikawa, Takayuki; Hattori, Katsuji; Kajimura, Mayumi; Suematsu, Makoto.

Advances in Experimental Medicine and Biology. Vol. 662 2010. p. 89-94 (Advances in Experimental Medicine and Biology; Vol. 662).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Morikawa, T, Hattori, K, Kajimura, M & Suematsu, M 2010, The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. in Advances in Experimental Medicine and Biology. vol. 662, Advances in Experimental Medicine and Biology, vol. 662, pp. 89-94. https://doi.org/10.1007/978-1-4419-1241-1_12
Morikawa T, Hattori K, Kajimura M, Suematsu M. The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. In Advances in Experimental Medicine and Biology. Vol. 662. 2010. p. 89-94. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-1241-1_12
Morikawa, Takayuki ; Hattori, Katsuji ; Kajimura, Mayumi ; Suematsu, Makoto. / The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. Advances in Experimental Medicine and Biology. Vol. 662 2010. pp. 89-94 (Advances in Experimental Medicine and Biology).
@inproceedings{cfccc64f04c5484eaae4fc0639e3136c,
title = "The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum",
abstract = "Although cilostazol, an inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3), is known to exert a potent antiplatelet function by raising intracellular cAMP concentration, its effect on cerebral microcirculation upon an ischemic insult is not clearly understood. To examine effects of cilostazol on the global ischemic injury in the brain, we first measured the plasma leakage using modified Miles assay after mice had been subjected to 60 min of a bilateral common carotid artery (BCCA) occlusion followed by reperfusion for 4 h. Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage. This result led us to examine if the treatment with cilostazol recruits more capillaries leading to an increase in surface area for exchange and oxygen transport to tissues. To do so, we simultaneously measured degrees of tissue hypoxia and vessel perfusion. Pimonidazol was injected intraperitoneally 1 h before sacrifice and capillary patency was assessed by fluorescein isothiocyanate-labeled Lycopersicon esculentum lectin bound to the endothelial surface. Treatment with cilostazol markedly increased the capillary patency which was accompanied by a reduction in the hypoxic area.Although the treatment with cilostazol caused an increase in the flux of plasma proteins across endothelial barrier that may imply an adverse role after a BCCA occlusion, this increase in protein leakage was attributable to the increased surface area for exchange which in turn brought about a reduction in tissue hypoxia. Taken together cilostazol appears to produce a protective effect against the ischemic-reperfusion injury.",
author = "Takayuki Morikawa and Katsuji Hattori and Mayumi Kajimura and Makoto Suematsu",
year = "2010",
doi = "10.1007/978-1-4419-1241-1_12",
language = "English",
isbn = "9781441912398",
volume = "662",
series = "Advances in Experimental Medicine and Biology",
pages = "89--94",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - GEN

T1 - The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum

AU - Morikawa, Takayuki

AU - Hattori, Katsuji

AU - Kajimura, Mayumi

AU - Suematsu, Makoto

PY - 2010

Y1 - 2010

N2 - Although cilostazol, an inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3), is known to exert a potent antiplatelet function by raising intracellular cAMP concentration, its effect on cerebral microcirculation upon an ischemic insult is not clearly understood. To examine effects of cilostazol on the global ischemic injury in the brain, we first measured the plasma leakage using modified Miles assay after mice had been subjected to 60 min of a bilateral common carotid artery (BCCA) occlusion followed by reperfusion for 4 h. Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage. This result led us to examine if the treatment with cilostazol recruits more capillaries leading to an increase in surface area for exchange and oxygen transport to tissues. To do so, we simultaneously measured degrees of tissue hypoxia and vessel perfusion. Pimonidazol was injected intraperitoneally 1 h before sacrifice and capillary patency was assessed by fluorescein isothiocyanate-labeled Lycopersicon esculentum lectin bound to the endothelial surface. Treatment with cilostazol markedly increased the capillary patency which was accompanied by a reduction in the hypoxic area.Although the treatment with cilostazol caused an increase in the flux of plasma proteins across endothelial barrier that may imply an adverse role after a BCCA occlusion, this increase in protein leakage was attributable to the increased surface area for exchange which in turn brought about a reduction in tissue hypoxia. Taken together cilostazol appears to produce a protective effect against the ischemic-reperfusion injury.

AB - Although cilostazol, an inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3), is known to exert a potent antiplatelet function by raising intracellular cAMP concentration, its effect on cerebral microcirculation upon an ischemic insult is not clearly understood. To examine effects of cilostazol on the global ischemic injury in the brain, we first measured the plasma leakage using modified Miles assay after mice had been subjected to 60 min of a bilateral common carotid artery (BCCA) occlusion followed by reperfusion for 4 h. Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage. This result led us to examine if the treatment with cilostazol recruits more capillaries leading to an increase in surface area for exchange and oxygen transport to tissues. To do so, we simultaneously measured degrees of tissue hypoxia and vessel perfusion. Pimonidazol was injected intraperitoneally 1 h before sacrifice and capillary patency was assessed by fluorescein isothiocyanate-labeled Lycopersicon esculentum lectin bound to the endothelial surface. Treatment with cilostazol markedly increased the capillary patency which was accompanied by a reduction in the hypoxic area.Although the treatment with cilostazol caused an increase in the flux of plasma proteins across endothelial barrier that may imply an adverse role after a BCCA occlusion, this increase in protein leakage was attributable to the increased surface area for exchange which in turn brought about a reduction in tissue hypoxia. Taken together cilostazol appears to produce a protective effect against the ischemic-reperfusion injury.

UR - http://www.scopus.com/inward/record.url?scp=77949904247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949904247&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1241-1_12

DO - 10.1007/978-1-4419-1241-1_12

M3 - Conference contribution

SN - 9781441912398

VL - 662

T3 - Advances in Experimental Medicine and Biology

SP - 89

EP - 94

BT - Advances in Experimental Medicine and Biology

ER -